MedPath

Nitazoxanide

Generic Name
Nitazoxanide
Brand Names
Alinia, Busulfex
Drug Type
Small Molecule
Chemical Formula
C12H9N3O5S
CAS Number
55981-09-4
Unique Ingredient Identifier
SOA12P041N
Background

Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .

Indication

用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。

Associated Conditions
Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia

Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients

Phase 2
Withdrawn
Conditions
covid19
Interventions
Drug: Placebo
First Posted Date
2020-06-22
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Registration Number
NCT04441398

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19

Phase 2
Withdrawn
Conditions
covid19
Interventions
Drug: Placebo
First Posted Date
2020-06-17
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Registration Number
NCT04435314

Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19

Phase 3
Recruiting
Conditions
covid19
Interventions
Drug: Placebo
First Posted Date
2020-06-09
Last Posted Date
2022-10-31
Lead Sponsor
Azidus Brasil
Target Recruit Count
380
Registration Number
NCT04423861
Locations
🇧🇷

Hospital Vera Cruz, Campinas, São Paulo, Brazil

Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children

Phase 3
Recruiting
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2020-06-04
Last Posted Date
2020-06-04
Lead Sponsor
Tanta University
Target Recruit Count
100
Registration Number
NCT04415983
Locations
🇪🇬

Sherief Abd-Elsalam, Tanta, Egypt

Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide

Phase 4
Completed
Conditions
Coronavirus Infection
Interventions
First Posted Date
2020-05-28
Last Posted Date
2021-03-30
Lead Sponsor
Materno-Perinatal Hospital of the State of Mexico
Target Recruit Count
150
Registration Number
NCT04406246
Locations
🇲🇽

Materno-Perinatal Hospital "Mónica Pretelini", Toluca, Mexico

Novel Regimens in COVID-19 Treatment

Phase 3
Recruiting
Conditions
COVID
Corona Virus Infection
Interventions
First Posted Date
2020-05-11
Last Posted Date
2020-12-04
Lead Sponsor
Tanta University
Target Recruit Count
160
Registration Number
NCT04382846
Locations
🇪🇬

Tanta University, Assiut University, Tanta, Egypt

🇪🇬

Sherief Abd-Elsalam, Tanta, Egypt

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

Phase 3
Completed
Conditions
COVID-19
Viral Respiratory Illnesses
Interventions
Drug: Placebo
Dietary Supplement: Vitamin Super B-Complex
First Posted Date
2020-04-24
Last Posted Date
2024-06-26
Lead Sponsor
Romark Laboratories L.C.
Target Recruit Count
1407
Registration Number
NCT04359680
Locations
🇺🇸

The Chappel Group Research, Kissimmee, Florida, United States

🇺🇸

Chicago Medical Research Institute, Inc., Chicago, Illinois, United States

🇺🇸

Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States

and more 22 locations

Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

Not Applicable
Completed
Conditions
COVID-19
Interventions
First Posted Date
2020-04-16
Last Posted Date
2022-10-28
Lead Sponsor
Azidus Brasil
Target Recruit Count
50
Registration Number
NCT04348409
Locations
🇧🇷

Hospital Vera Cruz, Campinas, São Paulo, Brazil

🇧🇷

Centro de Genomas, São Paulo, Brazil

🇧🇷

Hospital Emílio Ribas, São Paulo, Brazil

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Phase 3
Terminated
Conditions
COVID-19
Viral Respiratory Illnesses
Interventions
Drug: Placebo
Dietary Supplement: Vitamin Super B-Complex
First Posted Date
2020-04-13
Last Posted Date
2024-07-08
Lead Sponsor
Romark Laboratories L.C.
Target Recruit Count
190
Registration Number
NCT04343248
Locations
🇺🇸

The Chappel Group Research, Kissimmee, Florida, United States

🇺🇸

Clinical Trial Specialists, Inc., Acworth, Georgia, United States

🇺🇸

Centex Studies, Inc., Houston, Texas, United States

Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

Phase 4
Terminated
Conditions
Coronavirus Infection
Interventions
First Posted Date
2020-04-10
Last Posted Date
2021-04-01
Lead Sponsor
Hugo Mendieta Zeron
Target Recruit Count
44
Registration Number
NCT04341493
Locations
🇲🇽

Materno-Perinatal Hospital "Mónica Pretelini", Toluca, Mexico

© Copyright 2025. All Rights Reserved by MedPath